This article is more than 5 years old. Information may no longer be current.

Judah Folkman, MD, discussed his role in development of anti-angiogenic drugs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Judah Folkman, MD, discussed his involvement in the development of anti-angiogenic ocular therapy during his keynote address at the opening session of the American Academy of Ophthalmology annual meeting.

Judah Folkman, MD.

When Dr. Folkman and colleagues published the first paper on angiogenesis in 1971, "no one believed that tumors needed new blood supply," he said.

Today, multiple angiogenesis inhibitors are used globally to cure a number of ocular diseases, including age-related macular degeneration.